Dec 21 (Reuters) - Prima BioMed Ltd PRR.AX :
* Prima BioMed Ltd - data demonstrated activation and an increased level of blood monocytes, dendritic cells and CD8 T-cells
* Prima BioMed Ltd - IMP321 is safe and well tolerated
* Prima BioMed Ltd - subject to confirmation of dose escalation committee on 30 Dec, Prima will now commence randomised phase of trial in January 2017
* Prima BioMed Ltd - patients will receive paclitaxel treatment plus placebo or paclitaxel in conjunction with imp321
* Prima BioMed announces data from IMP321 AIPAC clinical trial in breast cancer Source text for Eikon: ID:nMKW6k6Cqa Further company coverage: PRR.AX